ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
혈우병 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 CAGR 8.8%로 209억 8,000만 달러로 성장합니다. 예측 기간 중의 성장은 R&D 혈우병 증가, 진단 검진 증가, 의료비 지출 증가, 전 세계적인 치료 접근성 증가에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 신약 출시 및 승인, 신약 개발 확대, 연구개발 및 임상시험, 디지털 헬스 솔루션, 치료 옵션의 발전 등이 있습니다.
향후 5년간 8.8%의 성장률 전망은 지난번 전망치보다 0.1% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 장벽은 스페인과 스위스에서 조달하는 유전자 재조합 응고인자 및 유전자 치료용 벡터의 비용을 상승시켜 치료 접근성을 방해하고, 출혈성 합병증 위험과 희귀질환에 대한 지출을 증가시킬 것으로 예측됩니다. 또한 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
혈우병 시장의 성장은 주로 유전자 이상 발생률 증가에 의해 주도될 것으로 예측됩니다. 유전자 이상은 유전자 돌연변이 또는 유전자 장애라고도 하며, 개인의 DNA 염기서열의 변화를 의미하며, 다양한 건강 상태나 신체적 특징을 유발할 수 있습니다. 혈우병 치료는 출혈 에피소드를 줄이거나 조절하고, 합병증을 줄이고, 유전자 이상을 가진 개인의 삶의 질을 향상시키는 것을 목표로 합니다. 예를 들어 2023년 6월, 영국에 기반을 두고 유전 질환을 가진 사람들을 지원하는 등록 자선단체인 진 피플스(Gene People)는 영국에서 25명 중 1명의 어린이가 유전 질환을 앓고 있으며, 매년 약 3만 명의 신생아 및 유아, 그리고 240만 명 이상의 어린이와 성인에게 영향을 미칩니다고 보고했습니다. 그 결과, 유전자 이상 발생이 증가하고 있는 것이 혈우병 시장 성장의 원동력이 되고 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 혈우병 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 혈우병 시장 : 성장률 분석
세계의 혈우병 시장 실적 : 규모와 성장, 2019-2024년
세계의 혈우병 시장 예측 : 규모와 성장, 2024-2029년, 2034년
세계의 혈우병 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 혈우병 시장 : 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
혈우병 A
혈우병 B
혈우병 C
기타 유형
세계의 혈우병 시장 : 치료별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
보충 요법
지혈제
데스모프레신
유전자 치료
기타 치료
세계의 혈우병 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
병원
클리닉
홈케어 설정
기타 최종사용자
세계의 혈우병 시장 : 서브 세분화 혈우병 A, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
고도 혈우병 A
중간 정도 혈우병 A
경도 혈우병 A
세계의 혈우병 시장 : 서브 세분화 혈우병 B, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
고도 혈우병 B
중간 정도 혈우병 B
경도 혈우병 B
세계의 혈우병 시장 : 서브 세분화 혈우병 C, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
고도 혈우병 C
경도 혈우병 C
세계의 혈우병 시장 : 서브 세분화 기타 유형(유형별), 실적과 예측, 2019-2024년, 2024-2029년, 2034년
후천성 혈우병
폰빌레브란트병
제7장 지역별·국가별 분석
세계의 혈우병 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
세계의 혈우병 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
혈우병 시장 : 경쟁 구도
혈우병 시장 : 기업 개요
Kedrion S.p.A. Overview, Products and Services, Strategy and Financial Analysis
Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
Sanofi S.A.
Bristol-Myers Squibb Company
Takeda Pharmaceutical Company Limited
Novo Nordisk A/S
Baxter International Inc.
CSL Limited
Biogen Inc.
Grifols S.A.
Octapharma AG
BioMarin Pharmaceutical Inc.
GC Pharma
Alnylam Pharmaceuticals Inc.
Bio Products Laboratory Ltd.
Sangamo Therapeutics Inc.
UniQure
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
혈우병 시장 2029년 : 새로운 기회를 제공하는 국가
혈우병 시장 2029년 : 새로운 기회를 제공하는 부문
혈우병 시장 2029년 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Hemophilia is a rare genetic disorder that affects the body's ability to clot blood properly and generally occurs when a person gets injured and starts bleeding. Hemophilia treatment treats Hemophilia disease through various medical interventions and strategies to manage and address the bleeding tendencies associated with hemophilia.
The main types of hemophilia are hemophilia A, hemophilia B, hemophilia C and others. Hemophilia A refers to a genetic disorder characterized by a deficiency of a protein called clotting factor VIII (factor 8). The various treatments include replacement therapy, hemostatic agents, desmopressin, gene therapy and others. These are used by various end-users such as hospitals, clinics, home care settings and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The hemophilia market research report is one of a series of new reports from The Business Research Company that provides hemophilia market statistics, including hemophilia industry global market size, regional shares, competitors with a hemophilia market share, detailed hemophilia market segments, market trends and opportunities and any further data you may need to thrive in the hemophilia industry. This hemophilia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hemophilia market size has grown strongly in recent years. It will grow from $13.83 billion in 2024 to $14.98 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to government initiatives, increased number of hemophilic patients, rising diagnostic screening, increasing awareness about hemophilia treatments.
The hemophilia market size is expected to see strong growth in the next few years. It will grow to $20.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising research and development hemophilias, rising diagnostic screening, incremental healthcare spending, global access to treatment. Major trends in the forecast period include new drug launches and approvals, escalation in novel drug development, research and clinical trials, digital health solutions, advancements in treatment options.
The forecast of 8.8% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper treatment access by increasing the cost of recombinant clotting factors and gene therapy vectors sourced from Spain and Switzerland, thereby risking bleeding complications and elevating rare disease expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growth of the hemophilia market is expected to be primarily driven by the rising incidence of genetic abnormalities. Genetic abnormalities, also known as genetic mutations or genetic disorders, refer to alterations in an individual's DNA sequence that can lead to various health conditions and physical traits. Hemophilia treatment aims to mitigate or control bleeding episodes, reduce complications, and enhance the quality of life for individuals with genetic abnormalities. For instance, in June 2023, Gene People, a UK-based registered charity organization supporting individuals with genetic conditions, reported that one in every 25 children in the UK had a genetic disorder, affecting approximately 30,000 newborns and young children in the country, as well as more than 2.4 million children and adults annually. Consequently, the increasing occurrence of genetic abnormalities is a driving force behind the growth of the hemophilia market.
The growth of the hemophilia market is expected to be driven by increasing investment efforts in hemophilia care. These efforts encompass the allocation of financial resources, research and development initiatives, and healthcare infrastructure enhancements, all aimed at advancing the treatment, management, and overall well-being of individuals with hemophilia. By improving access to hemophilia treatment, particularly in developing regions, these initiatives and partnerships work to expand the patient pool and market size. For example, in September 2022, the National Hemophilia Foundation (NHF), a nonprofit organization based in the United States, introduced Pathway to Cures (P2C), an innovative venture philanthropy investment fund with an initial funding of $3.5 million. P2C is dedicated to achieving substantial and transformative advancements in the field of inheritable blood disorders, capitalizing on its team's expertise in blood disorder research and leveraging NHF's valuable connections with scientific research institutions and clinical experts. Therefore, the increasing investment efforts in hemophilia care are expected to be a driving force behind the growth of the hemophilia market.
Major companies operating in the hemophilia market are focusing on the development of innovative drugs, such as ALTUVIIIO, to maintain their competitive position. For example, in February 2023, Sanofi S.A., a France-based pharmaceutical and healthcare company, introduced ALTUVIIIO for the treatment of hemophilia. This medication received approval from the US-based government agency, the Food and Drug Administration (FDA). ALTUVIIIO offers the unique benefit of once-weekly dosing, providing regular to near-normal factor activity levels (above 40%) for most of the week and significantly reducing bleeding compared to previous factor VIII prophylaxis.
In February 2023, Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical company specializing in hemophilia drugs, acquired Nimbus Therapeutics LLC for a sum of $4 billion. This strategic acquisition strengthens Takeda's late-stage pipeline and expands its portfolio, potentially broadening its impact on patients across multiple medical conditions. Nimbus Therapeutics LLC, a US-based pharmaceutical company, is engaged in the development and manufacturing of drugs for hemophilia.
Major companies operating in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Precision BioLogic Inc., Dimension Therapeutics, Chameleon Biosciences, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB.
North America was the largest region in the hemophilia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hemophilia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the hemophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, and Spain.
The hemophilia market consists of revenues earned by entities by providing physical therapy, hemophilia centers (HTCs) and prophylactic care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemophilia market consists of sales of hemophilia drugs and medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Hemophilia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on hemophilia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for hemophilia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hemophilia market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
2) By Treatment: Replacement Therapy; Hemostatic Agents; Desmopressin; Gene Therapy; Other Treatments
3) By End-User: Hospitals; Clinics; Home Care Settings; Other End-Users
Subsegments:
1) By Hemophilia A: Severe Hemophilia A; Moderate Hemophilia A; Mild Hemophilia A
2) By Hemophilia B: Severe Hemophilia B; Moderate Hemophilia B; Mild Hemophilia B
3) By Hemophilia C: Severe Hemophilia C; Mild Hemophilia C
4) By Other Types: Acquired Hemophilia; Von Willebrand Disease
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Hemophilia Market Characteristics
3. Hemophilia Market Trends And Strategies
4. Hemophilia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Hemophilia Growth Analysis And Strategic Analysis Framework
5.1. Global Hemophilia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Hemophilia Market Growth Rate Analysis
5.4. Global Hemophilia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Hemophilia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Hemophilia Total Addressable Market (TAM)
6. Hemophilia Market Segmentation
6.1. Global Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hemophilia A
Hemophilia B
Hemophilia C
Other Types
6.2. Global Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Replacement Therapy
Hemostatic Agents
Desmopressin
Gene Therapy
Other Treatments
6.3. Global Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Home Care Settings
Other End-Users
6.4. Global Hemophilia Market, Sub-Segmentation Of Hemophilia A, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Severe Hemophilia A
Moderate Hemophilia A
Mild Hemophilia A
6.5. Global Hemophilia Market, Sub-Segmentation Of Hemophilia B, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Severe Hemophilia B
Moderate Hemophilia B
Mild Hemophilia B
6.6. Global Hemophilia Market, Sub-Segmentation Of Hemophilia C, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Severe Hemophilia C
Mild Hemophilia C
6.7. Global Hemophilia Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acquired Hemophilia
Von Willebrand Disease
7. Hemophilia Market Regional And Country Analysis
7.1. Global Hemophilia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Hemophilia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Hemophilia Market
8.1. Asia-Pacific Hemophilia Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Hemophilia Market
9.1. China Hemophilia Market Overview
9.2. China Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Hemophilia Market
10.1. India Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Hemophilia Market
11.1. Japan Hemophilia Market Overview
11.2. Japan Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Hemophilia Market
12.1. Australia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Hemophilia Market
13.1. Indonesia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Hemophilia Market
14.1. South Korea Hemophilia Market Overview
14.2. South Korea Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Hemophilia Market
15.1. Western Europe Hemophilia Market Overview
15.2. Western Europe Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Hemophilia Market
16.1. UK Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Hemophilia Market
17.1. Germany Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Hemophilia Market
18.1. France Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Hemophilia Market
19.1. Italy Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Hemophilia Market
20.1. Spain Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Hemophilia Market
21.1. Eastern Europe Hemophilia Market Overview
21.2. Eastern Europe Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Hemophilia Market
22.1. Russia Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Hemophilia Market
23.1. North America Hemophilia Market Overview
23.2. North America Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Hemophilia Market
24.1. USA Hemophilia Market Overview
24.2. USA Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Hemophilia Market
25.1. Canada Hemophilia Market Overview
25.2. Canada Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Hemophilia Market
26.1. South America Hemophilia Market Overview
26.2. South America Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Hemophilia Market
27.1. Brazil Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Hemophilia Market
28.1. Middle East Hemophilia Market Overview
28.2. Middle East Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Hemophilia Market
29.1. Africa Hemophilia Market Overview
29.2. Africa Hemophilia Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Hemophilia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Hemophilia Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Hemophilia Market Competitive Landscape And Company Profiles
30.1. Hemophilia Market Competitive Landscape
30.2. Hemophilia Market Company Profiles
30.2.1. Kedrion S.p.A. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
31. Hemophilia Market Other Major And Innovative Companies
31.1. Sanofi S.A.
31.2. Bristol-Myers Squibb Company
31.3. Takeda Pharmaceutical Company Limited
31.4. Novo Nordisk A/S
31.5. Baxter International Inc.
31.6. CSL Limited
31.7. Biogen Inc.
31.8. Grifols S.A.
31.9. Octapharma AG
31.10. BioMarin Pharmaceutical Inc.
31.11. GC Pharma
31.12. Alnylam Pharmaceuticals Inc.
31.13. Bio Products Laboratory Ltd.
31.14. Sangamo Therapeutics Inc.
31.15. UniQure
32. Global Hemophilia Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Hemophilia Market
34. Recent Developments In The Hemophilia Market
35. Hemophilia Market High Potential Countries, Segments and Strategies
35.1 Hemophilia Market In 2029 - Countries Offering Most New Opportunities
35.2 Hemophilia Market In 2029 - Segments Offering Most New Opportunities
35.3 Hemophilia Market In 2029 - Growth Strategies
